Related Experiment Video
Updated: Jun 16, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
Published on: August 23, 2019
A potential microRNA signature for tumorigenic conazoles in mouse liver
Jeffrey A Ross1, Carl F Blackman, Sheau-Fung Thai
1Integrated Systems Toxicology Division, NHEERL, U.S. EPA, Research Triangle Park, North Carolina, USA.
Abstract:
Triadimefon, propiconazole, and myclobutanil are conazoles, an important class of agricultural fungicides. Triadimefon and propiconazole are mouse liver tumorigens, while myclobutanil is not. As part of a coordinated study to understand the molecular determinants of conazole tumorigenicity, we analyzed the microRNA expression levels in control and conazole-treated mice after 90 d of administration in feed. MicroRNAs (miRNAs) are small noncoding RNAs composed of approximately 19-24 nucleotides in length, and have been shown to interact with mRNA (usually 3' UTR) to suppress its expression. MicroRNAs play a key role in diverse biological processes, including development, cell proliferation, differentiation, and apoptosis. Groups of mice were fed either control diet or diet containing 1800 ppm triadimefon, 2500 ppm propiconazole, or 2000 ppm myclobutanil. MicroRNA was isolated from livers and analyzed using Superarray whole mouse genome miRNA PCR arrays from SABioscience. Data were analyzed using the significance analysis of microarrays (SAM) procedure. We identified those miRNAs whose expression was either increased or decreased relative to untreated controls with q < or = 0.01. The tumorigenic conazoles induced many more changes in miRNA expression than the nontumorigenic conazole. A group of 19 miRNAs was identified whose expression was significantly altered in both triadimefon- and propiconazole-treated animals but not in myclobutanil-treated animals. All but one of the altered miRNAs were downregulated compared to controls. This pattern of altered miRNA expression may represent a signature for tumorigenic conazole exposure in mouse liver after 90 d of treatment.
Insights
Tumorigenic conazoles like triadimefon and propiconazole significantly alter microRNA (miRNA) expression in mouse livers, unlike non-tumorigenic myclobutanil. This specific miRNA downregulation pattern may serve as a biomarker for conazole-induced liver tumorigenicity.
Area of Science:
- Toxicogenomics
- Molecular Biology
- Cancer Research
Background:
- Conazoles are widely used agricultural fungicides.
- Triadimefon and propiconazole are known mouse liver tumorigens, while myclobutanil is not.
- MicroRNAs (miRNAs) are small noncoding RNAs crucial for gene regulation and cellular processes.
Purpose of the Study:
- To investigate the molecular mechanisms underlying conazole-induced liver tumorigenicity.
- To identify specific microRNA expression changes associated with tumorigenic conazole exposure.
- To differentiate molecular responses between tumorigenic and non-tumorigenic conazoles.
Main Methods:
- Mice were administered triadimefon, propiconazole, or myclobutanil in their diet for 90 days.
- MicroRNA was isolated from liver tissues of control and treated mice.
- Whole mouse genome miRNA PCR arrays and Significance Analysis of Microarrays (SAM) were used to analyze miRNA expression levels.
Main Results:
- Tumorigenic conazoles (triadimefon, propiconazole) induced significantly more miRNA expression changes than non-tumorigenic myclobutanil.
- A distinct set of 19 miRNAs showed significantly altered expression in mice treated with both triadimefon and propiconazole, but not myclobutanil.
- The majority of these 19 altered miRNAs were downregulated in response to tumorigenic conazole exposure.
Conclusions:
- Altered miRNA expression profiles, particularly downregulation, may serve as a molecular signature for tumorigenic conazole exposure in mouse liver.
- This finding contributes to understanding the mechanisms of conazole-induced liver cancer.
- Further research could explore the diagnostic and prognostic potential of these miRNA signatures.
More Related Videos
09:45An In Vitro Protocol for Evaluating MicroRNA Levels, Functions, and Associated Target Genes in Tumor Cells
Published on: May 21, 2019
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
Related Concept Videos
MicroRNAs
MicroRNAs
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...